SSSang Mi Shin

Sang Mi Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sang Mi Shin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Ha Kim

    Department of Chemistry and Nanoscience, Ewha Womans University, 52, Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Republic of Korea

    1 shared publication
  • H K Kim

    Molecular Genetic Laboratory, College of Medicine, The Catholic University of Korea, Seoul, Korea

    1 shared publication
  • H-M Kang

    Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea

    1 shared publication
  • Hong Namkoong

    Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan

    1 shared publication
  • Ji Hye Yang

    College of Pharmacy, Chosun University, Seosuk-dong, Dong-gu, Gwangju 501-759, Republic of Korea

    1 shared publication
  • Jin-Wou Kim

    Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea

    1 shared publication

Latest Publications

  • Open Access

    Role of the Nrf2-ARE Pathway in Liver Diseases

    by Sang Mi Shin, Ji Hye Yang, Sung Hwan Ki

    The liver is a central organ that performs a wide range of functions such as detoxification and metabolic homeostasis. Since it is a metabolically active organ, liver is particularly susceptible to oxidative stress. It is well documented that liver diseases including hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma are highly associated with antioxidant capacity. NF-E2-related factor-2 (Nrf2) is an essential transcription factor that regulates an array of detoxifying and antioxidant defense genes expression in the liver. It is activated in response to electrophiles and induces its target genes by binding to the antioxidant response element (ARE). Therefore, the roles of the Nrf2-ARE pathway in liver diseases have been extensively investigated. Studies from several animal models suggest that the Nrf2-ARE pathway collectively exhibits diverse biological functions against viral hepatitis, alcoholic and nonalcoholic liver disease, fibrosis, and cancer via target gene expression. In this review, we will discuss the role of the Nrf2-ARE pathway in liver pathophysiology and the potential application of Nrf2 as a therapeutic target to prevent and treat liver diseases.


  • Gene expression signatures associated with the resistance to imatinib

    by Y-J Chung, T-M Kim, D-W Kim, H Namkoong, H K Kim, S-A Ha, S Kim, S M Shin, Y-J Lee, H-M Kang, et al.

    Imatinib (imatinib mesylate, STI-571, Gleevec) is a selective BCR-ABL tyrosine kinase inhibitor that has been used as a highly effective chemoagent for treating chronic myelogenous leukemia. However, the initial response to imatinib is often followed by the recurrence of a resistant form of the disease, which is major obstacle to many therapeutic modalities. The aim of this study was to identify the gene expression signatures that confer resistance to imatinib. A series of four resistant K562 sublines was established with different imatinib dosage (200, 400, 600 and 800 nM) and analyzed using microarray technology. The transcripts of the genes showing universal or dose-dependent expression changes across the resistant sublines were identified. The gene sets associated with the imatinib-resistance were also identified using gene set enrichment analysis. In the resistant K562 sublines, the transcription- and apoptosis-related expression signatures were upregulated, whereas those related to the protein and energy metabolism were downregulated. Several genes identified in this study such as IGF1 and RAB11A have the potential to become surrogate markers useful in a clinical evaluation of imatinib-resistant patients without BCR-ABL mutation. The expression signatures identified in this study provide insights into the mechanism of imatinib-resistance and are expected to facilitate the development of an effective diagnostic and therapeutic strategy.